News >

Cabozantinib QoL Similar to Everolimus in RCC Patients

Jason Harris
Published: Thursday, Feb 01, 2018

David Cella, PhD

David Cella, PhD
Patients with advanced renal cell carcinoma (RCC) treated with cabozantinib (Cabometyx) had similar quality of life (QoL) outcomes as those treated with everolimus (Afinitor).1


References

  1. Cella D, Escudier B, Tannir NM, et al. Quality of life outcomes for cabozantinib versus everolimus in patients with metastatic renal cell carcinoma: METEOR phase III randomized trial [published online January 29, 2018]. J Clin Oncol. doi: 10.1200/JCO.2017.75.2170.
  2. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med.2015;373(19):1814-1823.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x